Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Income from Continuing Operations (2016 - 2025)

Regenxbio has reported Income from Continuing Operations over the past 12 years, most recently at 67167000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 67167000.0 for Q4 2025, down 31.01% from a year ago — trailing twelve months through Dec 2025 was 193961000.0 (up 14.66% YoY), and the annual figure for FY2025 was 193961000.0, up 14.59%.
  • Income from Continuing Operations for Q4 2025 was 67167000.0 at Regenxbio, down from 61960000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for RGNX hit a ceiling of 294023000.0 in Q4 2021 and a floor of 76723000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 5 years was 61914000.0 (2023), compared with a mean of 27847550.0.
  • Peak annual rise in Income from Continuing Operations hit 392.34% in 2021, while the deepest fall reached 764.37% in 2021.
  • Regenxbio's Income from Continuing Operations stood at 294023000.0 in 2021, then dropped by 25.04% to 220406000.0 in 2022, then tumbled by 128.57% to 62969000.0 in 2023, then increased by 18.58% to 51269000.0 in 2024, then tumbled by 31.01% to 67167000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 67167000.0 (Q4 2025), 61960000.0 (Q3 2025), and 70892000.0 (Q2 2025) per Business Quant data.